Drug delivery system increasing the solubility of poorly-water soluble drugs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F19%3A43919293" target="_blank" >RIV/60461373:22340/19:43919293 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Drug delivery system increasing the solubility of poorly-water soluble drugs

Popis výsledku v původním jazyce

Challenge * Poor solubility of drugs, and their associated low dissolution rate in the aqueous gastrointestinal fluids, is one of the most frequent causes of low bioavailability, mainly in the case of oral dosage forms, which are the most commonly employed and convenient route of administration. Given that about 90 % of drugs in the discovery pipeline and over 40 % with market approved are insoluble or poorly-soluble in water, the pharmaceutical industry is focusing efforts in the development of strategies to improve the solubility of drugs in water. Technology * The invention relates to the formulation of composites comprised of yeast-derived beta glucan particles (GPs) and water-insoluble or poorly-water soluble drugs. The composites can exhibit different crystallinity degrees depending on the formulation and, consequently, dissolution kinetics can be controlled. Yeast-derived beta glucan particles are used as carriers for the encapsulation and amorphization of insoluble or poorly-water soluble drugs; amorphous formulations exhibiting faster dissolution rates, and consequently, enhanced drug bioavailability. The invention also relates to the method of preparation of the composites by spray drying, and the use thereof. Commercial Opportunity * The presented technology is targeted at pharmaceutical companies wanting to develop new drug forms with controlled dissolution kinetics and/or improved flowability and dispersibility properties. The invention is also targeted at food companies wanting to incorporate insoluble active ingredients into food products, e.g. vitamins or natural colorants such as curcumin. Development status * The encapsulation method has been fully developed. The produced composites were characterized in terms of crystallinity, dissolution kinetics, flowability, and dispersibility. Pharmacokinetic studies need to be done.

Název v anglickém jazyce

Drug delivery system increasing the solubility of poorly-water soluble drugs

Popis výsledku anglicky

Challenge * Poor solubility of drugs, and their associated low dissolution rate in the aqueous gastrointestinal fluids, is one of the most frequent causes of low bioavailability, mainly in the case of oral dosage forms, which are the most commonly employed and convenient route of administration. Given that about 90 % of drugs in the discovery pipeline and over 40 % with market approved are insoluble or poorly-soluble in water, the pharmaceutical industry is focusing efforts in the development of strategies to improve the solubility of drugs in water. Technology * The invention relates to the formulation of composites comprised of yeast-derived beta glucan particles (GPs) and water-insoluble or poorly-water soluble drugs. The composites can exhibit different crystallinity degrees depending on the formulation and, consequently, dissolution kinetics can be controlled. Yeast-derived beta glucan particles are used as carriers for the encapsulation and amorphization of insoluble or poorly-water soluble drugs; amorphous formulations exhibiting faster dissolution rates, and consequently, enhanced drug bioavailability. The invention also relates to the method of preparation of the composites by spray drying, and the use thereof. Commercial Opportunity * The presented technology is targeted at pharmaceutical companies wanting to develop new drug forms with controlled dissolution kinetics and/or improved flowability and dispersibility properties. The invention is also targeted at food companies wanting to incorporate insoluble active ingredients into food products, e.g. vitamins or natural colorants such as curcumin. Development status * The encapsulation method has been fully developed. The produced composites were characterized in terms of crystallinity, dissolution kinetics, flowability, and dispersibility. Pharmacokinetic studies need to be done.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

20401 - Chemical engineering (plants, products)

Projekt

<a href="/cs/project/NV16-27522A" target="_blank" >NV16-27522A: Přírodní bioaktivní látky enkapsulované v glukanových mikročásticích jako biomateriál vhodný pro léčbu střevních zánětlivých onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.